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Abstract
Background: Mortality among patients who complete tuberculosis (TB) treatment is still high among vulnerable
populations. The objective of the study was to identify the probability of death and its predictive factors in a cohort of
successfully treated TB patients.
Methods: A population-based retrospective longitudinal study was performed in Barcelona, Spain. All patients who
successfully completed TB treatment with culture-confirmation and available drug susceptibility testing between 1995–
1997 were retrospectively followed-up until December 31, 2005 by the Barcelona TB Control Program. Socio-demographic,
clinical, microbiological and treatment variables were examined. Mortality, TB Program and AIDS registries were reviewed.
Kaplan-Meier and a Cox regression methods with time-dependent covariates were used for the survival analysis, calculating
the hazard ratio (HR) with 95% confidence intervals (CI).
Results: Among the 762 included patients, the median age was 36 years, 520 (68.2%) were male, 178 (23.4%) HIV-infected,
and 208 (27.3%) were alcohol abusers. Of the 134 (17.6%) injecting drug users (IDU), 123 (91.8%) were HIV-infected. A total
of 30 (3.9%) recurrences and 173 deaths (22.7%) occurred (mortality rate: 3.4/100 person-years of follow-up). The predictors
of death were: age between 41–60 years old (HR: 3.5; CI:2.1–5.7), age greater than 60 years (HR: 14.6; CI:8.9–24), alcohol
abuse (HR: 1.7; CI:1.2–2.4) and HIV-infected IDU (HR: 7.9; CI:4.7–13.3).
Conclusions: The mortality rate among TB patients who completed treatment is associated with vulnerable populations
such as the elderly, alcohol abusers, and HIV-infected IDU. We therefore need to fight against poverty, and promote and
develop interventions and social policies directed towards these populations to improve their survival.
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Introduction
Tuberculosis (TB) continues to be one of the leading causes of
death from infectious diseases worldwide [1–2]. Its mortality
especially affects low income countries with high incidence rates of
human immunodeficiency virus (HIV) infection. However, in
developed countries, where TB is less common and mortality has
gradually declined in recent decades, TB patients also die, though
not always from TB itself [3–7].
Various studies have reported TB mortality and associated
factors during active disease [4–5,7–9] and have emphasized the
importance of treatment adherence to reduce the probability of
dying [3,7–11]. However, there is little data about the long-term
survival for successfully treated TB patients. It has been suggested
that the treatment outcome may not reflect final patient status, in
part due to pulmonary impairment after TB disease [12]. This has
implications for patient care, such as more aggressive case
prevention strategies and post-treatment evaluation, as well as
for TB control of default and lost to follow-up cases [12–14].
The HIV and injecting drug users (IDU) epidemics in
developed countries during the 1990’s had a considerable impact
on TB rates and mortality [15,16]. It is therefore of interest to
determine the status of the TB patients who survived and whether
they still represent a vulnerable group, despite drug abuse care
programs and the use of highly active antiretroviral therapy
(HAART).
The identification of the characteristics of patients who die
prematurely will help identify the most vulnerable populations
and help to target them in future public health interventions.
Therefore, the aim of this study was to determine the incidence of
death and its predictors in a cohort of successfully treated TB
patients.
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Materials and Methods
Ethics statement
Demographic and clinical data were obtained from the
epidemiological questionnaire used by TB Prevention and Control
Program (TBPCP). The data was treated and analysed anony-
mously. The analysis was carried out retrospectively and involved
data collected on a routine basis within the National Tuberculosis
Program approved by the Spanish Ministry of Health. Therefore,
no ethical approval nor informed consent was required. All data
were treated in a strictly confidential manner following the ethical
principles of the Helsinki Declaration of 1964 revised by the World
Medical Organization in Edinburgh, 2000 and the Organic Law
15/1999 of Data Protection in Spain.
Setting
The study was conducted in Barcelona (Catalonia, Spain),
which had a population of 1,508,805 inhabitants living in an area
of 100.4 square km during the enrollment period. The TBPCP has
been operating in the city since 1987.
Study design and population
This retrospective population-based cohort study included all
patients detected by the TBPCP who began treatment between
October 1st, 1995 and October 31st, 1997, with culture
confirmation and drug susceptibility testing (DST) results, and
who resided in the city of Barcelona. Cases that completed
treatment according to the European recommended treatment
outcome definition [17] were selected and followed to determine
mortality rates and factors associated with death. The follow-up
period continued until December 31st, 2005, at which time all
cases were classified as either survived, transferred, or dead.
Definitions
A ‘‘definite TB case’’ was defined using international recom-
mendations [14]: a patient was considered to have TB if the
culture was positive for M. tuberculosis complex. All patients who
completed TB treatment, regardless of the availability of
bacteriological confirmation, were considered cured [8,18]. TB
recurrence was defined as any new clinical and/or microbiological
TB diagnosis presented by a patient who completed treatment
after being TB disease-free for at least one year since treatment
completion [19–20].
Variables and information sources
All data came from the Barcelona TBPCP epidemiological
surveys preformed by public health nurses on all detected cases.
The Epidemiology Service collects data on TB and AIDS cases
reported by physicians and also performs active surveillance for
undeclared cases (via microbiological laboratories, hospital
discharges, the city mortality registry, and social services). Socio-
demographic variables included age, sex, country of birth (foreign
or Spain), city district residence (inner-city or other), homelessness,
prison history, smoking, alcohol abuse and IDU. Consumption of
over 280 g of alcohol per week for men and over 168 g for women
was considered alcohol abuse. Clinical variables included presence
of HIV infection and route of infection, recurrence, type of TB
(pulmonary, extrapulmonary or both (mixed TB) and chest
radiograph results (abnormal non-cavitary, normal, or caviatry).
Microbiological and treatment variables included smear test
results, type of resistance (none, primary or secondary), drug
resistance to isoniazid and rifampin (multi-drug resistance, or
MDR), previous TB treatment, and treatment under directly
observed treatment (DOT). DOT was used for some patient
groups and defined as a observation from a healthcare worker of a
patient as they take their TB medication. Primary resistance was
defined as the presence of resistance to one or more anti-TB drugs
in strains obtained from patients who had never received
treatment. Secondary resistance was defined as resistance to one
or more anti-TB drugs in strains recovered from patients who had
received previous anti-TB treatment.
After a patient was included in the study, they were actively
followed to verify vital status at the end of the study, as well as any
recurrent TB episode during the follow up and/or date of transfer-
out. Hospital clinical records, primary health care registries, the
municipal census, the city mortality registry, and the Barcelona
city drug abuse information system were reviewed to minimize lost
to follow-up patients and compare duplicated information. At the
end of the study, patients were considered to be lost to follow-up if
no vital status or moving date was available.
Statistical analysis
A descriptive analysis of the cohort was preformed, which
included the medians and interquartile range (IQR) for quanti-
tative variables, because none of the quantitative variables
displayed normal distribution. The x2 test was used for categorical
variables and two-sided Fisher test were used when applicable.
The overall mortality rate was calculated, as well as that specific to
immigrants, HIV-infected patients and IDU, expressed in terms of
cases per 100 person-years of follow-up (PY) and relative risks
(RR). Follow-up time to death, transfer out, or end of the study
was calculated in reference to the time elapsed since the end of TB
treatment.
Patients who died were compared to the rest of the cohort. In
the bivariate analysis, survival curves were estimated using the
Kaplan-Meier curves and were compared using the Log-rank test.
Possible interactions between patient clinical and demographic
characteristics were considered and a forward inclusion approach
was used. On a multivariate level, a Cox proportional hazards
regression was preformed with time dependent covariates in
relation to TB recurrence. Variables significantly correlated at the
univariate level (p-value,0.10), and those of epidemiological
interest. Hazard Ratios (HR) with their 95% confidence intervals
(CI) were used to measure association. The proportional hazards
assumption was tested by graphical methods and by goodness-of-
fit analysis using Schoenfeld residuals. Analyses were preformed
using the statistical packages: SPSS, v. 13.0 (SPSS Inc., Chicago,
IL, USA) and R, v. 2.6.0 (The R Foundation for Statistical
Computing).
Results
Cohort selection
Figure 1 shows the flow-chart of cohort selection. Of the 999
(80.7%) patients with culture Mycobacterium tuberculosis growth and
DST results, 762 (76.3%) cases correctly completed treatment and
thus constituted the study cohort, 6 (0.6%) died from causes
attributed to TB, 150 (15%) died due to other causes before
finalizing treatment, 45 (4.5%) moved outside of Catalonia, Spain
during treatment, and 36 (3.6%) were lost to follow-up before
completing treatment.
Cohort description
The median age of the cohort was 36 years (IQR 28–52), with a
predominance of men, Spanish patients, smokers and alcohol
abusers. One in a five patients lived in the inner-city district. The
most frequent presentation of TB was pulmonary (PTB), followed
by extra-pulmonary TB. Smear test results were positive in 419
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(55%) cases. A total of 35 (4.6%) patients presented with some
primary drug resistance, while 13 (1.7%) presented with some
secondary drug resistance. During the follow-up, there were 30
(3.9%) cases of recurrence; 26 (86.7%) in men and 4 (13.3%) in
women. Table 1 shows socio-demographic, clinical, microbiolog-
ical and treatment characteristics by vital status at the end of the
follow-up.
Regarding TB risk factors, 134 (17.6%) were IDU and 178
(23.4%) were infected with HIV. Of the 134 IDU cases, 123
(91.8%) were HIV-infected. Regarding HIV transmission, 123
(69.1%) were IDU, 30 (16.9%) were heterosexual non-IDU, 16
(8.9%) were homosexual non-IDU, and the route of HIV infection
was unknown in 9 (5.1%) cases.
The median follow-up duration among patients who completed
TB treatment was 8.04 years (IQR 5.8–8.8). At the end of follow-
up, 173 (22.7%) patients had died, 83 (10.9%) had moved outside
of Catalonia, Spain, and a total of 506 (66.4%) were alive. The
patients who died were older, male, Spanish, residents in the
inner-city, alcohol abusers and HIV-infected IDU. Table 1
compares the patients who died during follow-up with the
survivors. None of the 11 non-HIV-infected IDU died during
follow-up and were excluded from the multivariate analysis.
Mortality rates
The mortality rate among the 762 patients who correctly
completed treatment was 3.4/100 PY, or 3,355/100,000 PY of
follow-up (1.6/100 PY among,41 years, 2.9/100 PY among 41–
60 and 8.4/100 PY among.60 years and 9.3/100 PY among.64
years old patients). The rate among IDU and among HIV-infected
patients was 6.5/100 PY (RR: 2.0 CI: 1.5–2.6) and 5.9/100 PY
(RR: 1.8 CI: 1.4–2.3), respectively. Among immigrant and native
populations, mortality was 1.5/100 PY (RR: 0.3 CI: 0.2–0.8) and
3.5/100 PY (RR: 2.9 CI: 1.3–6.3), respectively.
The median duration of follow-up after TB treatment
completion and prior to death was 3.7 (IQR 1.5–6.3) years. The
cumulative probabilities of dying at 1, 3, 6 and 9 years of follow-up
were 4.5, 11.1, 17.7, and 25.9 percent, respectively. The incidence
of recurrence was 0.5/100 PY, or 530 cases per 100,000
inhabitants; 1.1/100 PY among HIV-infected patients, and 0.4/
100 PY among non-HIV-infected.
Factors associated with death
The following factors were significantly associated with death on
a univariate level: male, age over 41 years, born in Spain,
residence in the inner-city, alcohol, HIV-infected IDU, mixed TB,
treatment under DOT, cavitary and normal chest-X-ray, and
previous TB treatment (Table 2 and Figures 2, 3, 4). On the
multivariate level, age was associated with death, with a significant
gradient and 3.5-fold higher risk of dying after an age 41 years.
HIV-infection and IDU were also significantly associated with a
7.9-fold higher risk of dying. Alcohol abusers had a 1.7 times
higher risk. TB recurrence was not found to be significantly
associated with death (Table 2).
Discussion
Factors such as alcohol abuse, age, and being an HIV-infected
IDU are associated with a higher risk of death, despite treatment
completion for an episode of TB while TB recurrence or being
non-IDU HIV infection were not associated. Several studies
have analyzed the probability of dying during TB treatment [4–
9,20], but only few study patients who completed TB treatment to
identify factors associated with the probability of dying [13,14,
21,22].
Almost a quarter of the study population died during the 8-year
follow-up period. Mortality rate in our study population was
higher (3,355 per 100,000 PY) compared to that of the general
population (general mortality rate: 1,147 per 100,000 inhabitants)
and mortality rate among older then 64 years was also higher
(9,285 per 100,000 PY) compared to that of the general
population.64 years old (4,843 per 100,000 PY) [23]. Higher
mortality rate could be due to the considerable number of IDU,
and high percentage HIV-infected IDU. Similarly, literature from
the USA [12,24], the Netherlands [21] and Finland [25] claim
that TB patients have a higher risk of dying than the general
population during TB treatment. However, it has also been
suggested that the final treatment outcome may not reflect the
patient’s final status, perhaps in part due to pulmonary
impairment after an episode of TB. This disease can produce
changes and chronic lesions in the lungs such as bronchiectasis,
pulmonary fibrosis that have been shown to be associated with
decreased survival [12].
According to previous studies, the following factors were
associated with death: age [5–8,23], HIV infection [5,8,9,14,24],
being IDU [8,15,19,24] and alcohol abuse [5,8,24]. It has also been
suggested that an increase in the risk of death may not be due to TB,
but rather to individual factors such as HIV infection, alcohol or
drug abuse, and precarious living conditions [8,22,25]. These
modifiable risk factors provide a possibility of improvement through
prevention and/or treatment; thus adherence to HAART among
IDU patients should be warranted. Age, a non-modifiable factor,
can also influence the final patient outcome. For example, older
patients may experience longer diagnostic delays due to different
clinical manifestations than younger patients [25–28]. The delay in
diagnosing TB, probably due to the associated morbidity, as well as
Figure 1. Flow chart of tuberculosis patient selection and
evolution. Barcelona, 1995–2005.
doi:10.1371/journal.pone.0025315.g001
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their lower immunity status in the older populations have been
suggested as possible explanations for their increased mortality [28].
As expected in our setting [29], a considerable proportion of
HIV-infected TB patients (23.4%) were IDU. Some studies have
shown an increased mortality of up to 10 times higher in co-
infected patients compared to non HIV-infected TB patients
during the pre-HAART era. The increased use of HAART, which
is effective and widespread in many high income countries but
very often lacking in most rural areas in the low income countries,
has led to changes in mortality among TB/HIV co-infected
patients [30]. In Spain, HAART became available and free of cost
in 1996. Unlike any other study [26,31], we observed that co-
infection with HIV among non-IDU is not associated with
mortality. This could possibly be due to of better adherence to
HAART than within the IDU population.
It is known that patients previously treated for TB have a higher
risk of presenting MDR TB [31–33] and of dying [34] than new
TB patients. However, in our study, previous TB treatment was
not associated to mortality in the adjusted model. Abnormal non-
cavitary and cavitary chest-X-ray were not associated to mortality
in the adjusted model. Nevertheless, cavitary chest-X-ray showed a
protection against mortality tendency at multivariate level (p-value
0.056) probably due to the well known association between good
immune system and cavitary TB [35]. Type of TB was highly
correlated with chest-X-Ray variable and was therefore excluded
from the adjusted model.
Contrary to results of studies performed in the USA, the
European Union, Mexico, or Azerbaijan [7–13,36,37], we did not
find any association between MDR TB and mortality perhaps
because our study population consisted of patients who completed
TB treatment. Among the 156 excluded patients who died during
treatment, only four of them (2.6%) were MDR-TB, 42 (26.9%)
were IDU, and 59 (37.8%) were HIV-infected. Sixty-seven died in
1995–1996, when HAART treatment was still not as available.
The prevalence of MDR-TB in our city is low because of the
universal use of Fixed Dose Combination treatment and extensive
DOT among vulnerable populations.
Table 1. Distribution of characteristics of the cohort of 762
patients according to vital status at the end of follow-up.
Barcelona, 1995–2005.
Variables
Total
n (%)
762 (100)
Died
n (%)
173 (22.7)
Survived
n (%)
589 (77.3) p-value
Median age
(years) (IQR)*
36 (28–52) 56 (36–71.5) 34 (27–46) ,0.001
Sex
. Male 520 (68.2) 134 (77.5) 386 (65.5) 0.002
. Female 242 (31.8) 39 (22.5) 203 (34.5)
Country of birth
. Foreign 72 (9.4) 6 (3.5) 66 (11.2) 0.001
. Spain 690 (90.6) 167 (96.5) 523 (88.8)
Residence in inner-city
. Yes 152 (19.9) 40 (23.1) 112 (19) 0.010
. No 610 (80.1) 133 (76.9) 477 (81)
Homelessness
. Yes 53 (7) 15 (8.7) 38 (6.5) 0.340
. No 709 (93) 158 (91.3) 551 (93.5)
Prison history
. Yes 69 (9.1) 20 (11.6) 49 (8.3) 0.370
. No 693 (90.9) 153 (88.4) 540 (91.7)
Smoker
. Yes 414 (54.3) 94 (54.3) 320 (54.3) 0.450
. No 331 (43.4) 73 (42.2) 258 (43.8)
. Unknown 17 (2.2) 6 (3.5) 11 (1.9)
Alcohol abuse
. Yes 208 (27.3) 69 (39.9) 139 (23.6) ,0.001
. No 554 (72.7) 104 (60.1) 450 (76.4)
HIV-IDU**
. HIV Negative - Non-IDU 573 (75.2) 112 (64.7) 461 (78.3) ,0.001
. HIV Positive –IDU 123 (16.1) 51 (29.5) 72 (12.2)
. HIV Positive - Non-IDU 55 (7.2) 10 (5.8) 45 (7.6)
. HIV Negative –IDU 11 (1.4) 0 (0) 11 (1.9)
Recurrence
. Yes 30 (3.9) 6 (3.5) 24 (4.1) 0.810
. No 732 (96.1) 167 (96.5) 565 (95.9)
Type of tuberculosis
. Pulmonary 573 (75.2) 118 (68.2) 455 (77.2) 0.038
. Mixed 78 (10.2) 25 (14.5) 53 (9)
. Extrapulmonary 111 (14.6) 30 (17.3) 81 (13.8)
Chest- X-Ray
. Abnormal non-cavitary 447 (58.7) 109 (63) 338 (57.4) ,0.001
. Cavitary 225 (29.5) 33 (19.1) 192 (32.6)
. Normal 77 (10.1) 28 (16.2) 49 (8.3)
. Unknown 13 (1.7) 3 (1.7) 10 (1.7)
Type of resistance
. No resistance 705 (92.5) 157 (90.8) 548 (93) 0.860
. Primary 35 (4.6) 8 (4.6) 27 (4.6)
. Secondary 13 (1.7) 3 (1.7) 10 (1.7)
. Unknown 9 (1.2) 5 (2.9) 4 (0.7)
Variables
Total
n (%)
762 (100)
Died
n (%)
173 (22.7)
Survived
n (%)
589 (77.3) p-value
MDR TB***
. Yes 11 (1.4) 3 (1.7) 8 (1.4) 0.900
. No 747 (88.1) 168 (97.1) 579 (98.3)
. Unknown 4 (0.5) 2 (1.2) 2 (0.3)
Previous TB treatment
. Yes 116 (15.2) 33 (19.1) 83 (14.1) 0.078
. No 618 (81.1) 130 (75.1) 488 (82.9)
. Unknown 28 (3.7) 10 (5.8) 18 (3.1)
DOT****
. No 623 (81.8) 123 (71.1) 500 (84.9)
. Yes 139 (18.2) 50 (28.9) 89 (15.1) ,0.001
*IQR: Interquartile range.
**IDU: Injecting drug users.
***MDR TB: Multi-drug resistant tuberculosis.
****DOT: Directly observed treatment.
doi:10.1371/journal.pone.0025315.t001
Table 1. Cont.
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Despite existing evidence concerning the association of smoking
with death and with TB [38,39], we did not find a relationship
between smoking and mortality (HR: 1.1 (CI 0.8–1.4), perhaps
because the effects of tobacco occur over a longer period of time
than our follow-up period of only eight years. We also found no
effect of being foreign born on mortality, although some of the
foreign born may have returned to their home countries and the
final status was not recorded for some cases. Adjusting for type of
TB instead of chest-X-Ray (correlated variables), disseminated TB
presentation (mixed TB) was not associated with a higher risk of
mortality as reported in a study from the USA [24]. As in similar
settings [8], DOT was associated with a higher risk of death
because it is usually implemented in the most vulnerable
populations such as HIV infected, IDUs and alcohol abusers.
Thus, it was considered as a confounder and not included in the
multivariate analysis.
High TB recurrence rates have been reported in countries with
high TB incidence and limited control programs [13,22]. The
recurrence rate found during the follow-up among our study
population is one of the lowest when compared to those reported
in recent publications [22,40–43], ranging between 0–14%.
Possible reasons for the recurrent rates in our study include lower
TB incidence, smaller percentages of MDR TB, and/or varying
inclusion criteria and definitions [40]. The existence of an effective
TBPCP, which has prioritized the use of DOT strategy among
high-risk groups to achieve compliance rates of 95% since 1995
[5,8], could have also influenced our results. Additionally, few
studies have assessed the influence of TB recurrence on mortality.
We found that TB recurrence among patients who completed
treatment was not associated with a higher risk of mortality. This
was also observed in low incidence settings, such the USA [24],
but not in high incidence settings such as Uzbekistan [13]. These
Table 2. Factors associated with death in a cohort of 762 successfully treated tuberculosis patients. Barcelona, 1995–2005.
Univariate Analysis Multivariate Analysis
Variables Hazard Ratio 95%CI p-value Hazard Ratio 95%CI p-value
Age (years)
. Under 41 1 - - 1 - -
. 41 to 60 1.9 1.3–2.8 0.002 3.5 2.1–5.7 ,0.001
. Older than 60 5.3 3.8–7.5 ,0.001 14.6 8.9–24 ,0.001
Sex
. Female 1 - - 1 - -
. Male 1.7 1.2–2.4 0.005 1.1 0.8–1.7 0.795
Country of origin
. Foreign 1 - - 1 - -
. Spain 2.4 1.1–5.5 0.030 1.5 0.7–3.5 0.315
Residence in inner-city
. No 1 - - 1 - -
. Yes 1.4 1–2 0.060 1.2 1.8–1.7 0.335
Alcohol abuse
. No 1 - - 1 - -
. Yes 1.9 1.4–2.6 ,0.001 1.7 1.2–2.4 0.003
HIV-IDU*
. HIV Neg- Non-IDU 1 - - 1 - -
. HIV and IDU 2.6 1.9–3.7 ,0.001 7.7 4.5–13.3 ,0.001
. HIV not IDU 1 0.5–2 0.953 1.4 0.7–2.8 0.350
TB** recurrence
. No 1 - - 1 - -
. Yes 1.6 0.7–3.7 0.237 0.8 0.3–2 0.563
Chest- X-Ray
.Abnormal non-cavitary 1 - - 1 - -
. Cavitary 1.6 1.1–2.4 0.028 1.3 0.8–2.2 0.235
. Normal 0.6 0.4–0.9 0.008 0.7 0.5–1 0.068
. Unknown 0.9 0.3–2.9 0.890 0.7 0.2–2.2 0.521
Previous TB treatment
. Yes 1 - - 1 - -
. No 1.6 1.1–2.3 0.020 1.3 0.9–2.1 0.185
. Unknown 2.2 1.2–4.2 0.015 1.1 0.6–2.4 0.719
*IDU: injecting drug users.
**TB: Tuberculosis.
doi:10.1371/journal.pone.0025315.t002
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Figure 2. Kaplan Meier curves of the risk of death in a cohort of tuberculosis patients according to age group. Barcelona, 1995–2005.
doi:10.1371/journal.pone.0025315.g002
Figure 3. Kaplan Meier curves of the risk of death in a cohort of tuberculosis patients according to HIV infection and IDU status.
Barcelona, 1995–2005.
doi:10.1371/journal.pone.0025315.g003
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differences could be due in part to the relapse and recurrence
definitions. Above all, the lack of an association between TB
recurrence and mortality in our study could be due to a high
percentage (over 80%) of recurrent cases that correctly underwent
treatment for their second TB episode.
Sputum samples frequently cannot be obtained from patients
who complete treatment. For this reason and because the
prevalence of drug-resistance is low, we considered treatment
completion to be a good approximation for cured [13,18].
Mortality data among HIV, alcohol and drug abusers in the
general population was not available. Therefore, performing direct
comparisons and calculations among these hidden populations is
not possible. Other possible limitations of this population-based
study include the limited access to clinical data such as HAART
treatment and CD4 cell count, the limited presence of sub-
populations who are usually culture negative such as children, and
the absence of appropriate molecular techniques to determine if
recurrence was due to reactivation of the same TB strain or due to
re-infection by a different strain [44]. Identification of the origin of
recurrence could have further implications in public health policy
for TB [13,31,42–44]. Though the percent of lost to follow-up
patients was small (3.6%), we compared lost to follow-up patients
to the patients included in our analysis and found that the lost to
follow-up population had a larger presence of foreign-born and
inner-district residents. These patients could be underrepresented
and could have perhaps skewed our final results in some way.
We conclude that HIV-infected IDU, those over 41 years old,
and alcohol abusers have a poor long-term prognosis after
completing TB treatment while TB recurrence and MDR TB
are not associated with mortality when the first episode is
successfully treated. The decrease in mortality among TB patients
requires new public health interventions [44] and the enhance-
ment of existing control programs to improve both prevention and
treatment. Interventions should be directed at modifiable risk
factors, such as alcohol abuse, treatment of HIV-infection and
treatment of IDU patients. Priority must be given to promote
relevant social policies to fight against poverty and achieve a
decline of the mortality as well as an improvement in the quality of
life and perceived health status of our patients.
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